BOSTON, Mass. — VectorY Therapeutics has appointed Kevin Pojasek, Ph.D., to its board of directors, adding a seasoned biotechnology executive with more than 20 years of experience in company creation, corporate strategy, and drug development.
Pojasek currently serves as president and chief executive officer of Enara Bio, where he has led the company since 2018 and guided its efforts to develop T-cell engager therapies targeting novel solid tumor antigens. He is also a venture partner at SV Health Investors and previously served as an entrepreneur-in-residence at Atlas Venture.
Before joining Enara, Pojasek was chief strategy and business officer at Immunocore, where he helped shape corporate and research strategy and led business development initiatives. Earlier in his career, he co-founded Quartet Medicine while at Atlas Venture and served as the company’s president and chief executive officer. He has held multiple senior leadership roles across research and development, corporate strategy, and business development at venture-backed biotechnology companies.
“Kevin’s track record of building and guiding high-impact biotech companies makes him an exceptional addition to our board,” said Adam Rosenberg, chair of the board at VectorY. “His strategic insight and deep industry experience will be invaluable as we continue to advance new approaches to address unmet treatment needs in neurodegenerative disease.”
“I’m pleased to join the VectorY team at this important stage of the company’s growth,” Pojasek said. “The company’s mission to advance vectorized antibody therapies to create disease-modifying treatments that could reverse neurodegenerative disease strongly resonates with me, and I look forward to supporting the team as it advances its platform and enters its next phase of growth.”
Pojasek earned his Ph.D. in biological engineering from the Massachusetts Institute of Technology and a bachelor’s degree in molecular, cellular, and developmental biology from the University of Colorado.
